Abstract
We previously reported a novel differentiation antigen, which is specifically expressed in stage II double positive (CD4+CD8+) human cortical thymocytes (Park et al, J Exp Med 1993; 178: 1447–1451). This study was designed to investigate the expression pattern of JL1 in various types of leukemic cells from patients and normal hematopoietic cells to evaluate the possibility as a tool for diagnosis and treatment of leukemia. The expression of JL1 antigen was observed in 75.6% of leukemic cases (117 out of 154 leukemic patients tested) on flow cytometric analysis. The percentage of JL1-positive cases of T lineage acute lymphoblastic leukemia (T-ALL) (92.6%) was higher than that of other types of leukemias (75%). The presence of JL1 antigen was also confirmed by immunoblotting and immunoprecipitation. Since the JL1 antigen is selectively expressed on the surface of human leukemic cells but not on the mature human peripheral blood cells, normal bone marrow cells and various types of normal tissues, JL1 could be an excellent candidate for an immunodiagnostic and immunotherapeutic tool for hematopoietic malignancies such as leukemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Park, W., Bae, Y., Chung, D. et al. A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias. Leukemia 12, 1583–1590 (1998). https://doi.org/10.1038/sj.leu.2401161
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401161
Keywords
This article is cited by
-
Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo
Cancer Immunology, Immunotherapy (2021)
-
Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia
Cancer Immunology, Immunotherapy (2011)
-
Expression of JL1 in Burkitt lymphoma is associated with improved overall survival
Virchows Archiv (2011)
-
Leukemia-Specific siRNA Delivery by Immunonanoplexes Consisting of Anti-JL1 Minibody Conjugated to Oligo-9 Arg-Peptides
Molecules and Cells (2010)